LoginSign Up
Kallyope

Kallyope

Kallyope is a New York City, New York based biotechnology company founded in 2015 developing therapeutics to improve human health by better understanding the gut-brain relationship.

Kallyope is a biotechnology and therapeutic microbiome company that was founded by Charles Zucker, Tom Maniatis, and Richard Axel in 2015 that is headquartered in New York City, New York. Kallyope uses gene sequencing, computational biology, neural imaging, cellular/molecular biology, and human genetics to understand the relationship between the human gut and the human brain in combination with their own drug discovery expertise to develop effective gut-brain therapies that improve human health and nutrition.

Funding

Series A

On December 10, 2015 Kallyope closed their series A funding round with $44 million in funding from The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Alexandria Venture investments, and Tony Evnin.

Series B

On February 22, 2018 Kallyope closed their series B funding round with $66 million in funding from Two Sigma Ventures, The Column Group, Polaris Partners, Lux Capital, Illumina Ventures, Euclidean Capital, and Alexandria Venture Investments.

Timeline

People

Name
Role
Related Golden topics

Ann Weber

SVP, Drug Discovery

Charles Zuker

Co-founder

Nancy Thornberry

CEO

Richard Axel

Co-founder

Rob Anstey

VP, Business Development

Tom Maniatis

Co-founder

Further reading

Title
Author
Link
Type

Kallyope and Novo Nordisk Team Up To Tackle Obesity | BioSpace

Mark Terry

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References